The burden of HIV-associated neurocognitive impairment in Australia and its estimates for the future
Lucette A. Cysique A , Margaret P. Bain B , Bruce J. Brew A B and John M. Murray C D EA Brain Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
B Department of Neurology, St. Vincent’s Hospital, Sydney, NSW 2010, Australia.
C School of Mathematics and Statistics, University of New South Wales, Sydney, NSW 2052, Australia.
D The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
E Corresponding author. Email: J.Murray@unsw.edu.au
Sexual Health 8(4) 541-550 https://doi.org/10.1071/SH11003
Submitted: 13 January 2011 Accepted: 6 May 2011 Published: 29 July 2011
Abstract
Background: The growing number of older individuals with HIV in Australia implies that the prevalence of dementia and additional HIV-associated neurocognitive disorders will increase. There are currently no estimates of the future burden of neurocognitive disease in this population. Methods: We estimated the number and age profile of people living with HIV to the end of 2009 using HIV/AIDS Registry data, and extrapolated these estimates to 2030. Prevalence of HIV-associated dementia (HAD) from 2005 to 2010 from a large Sydney hospital and cost estimates from the AIDS Dementia and HIV Psychiatry Service were used to estimate future HAD burden and costs. Results: Based on our calculations, the number of HIV-positive individuals in Australia will increase from 16 228 men and 1797 women in 2009 to 26 963 men and 5224 women in 2030, while the number of individuals aged 60+ years will increase from 1140 men and 78 women to 5442 men and 721 women, i.e. a 377% increase of older men and an 825% increase in older women. Based on a 7.8% (157/2004) HAD prevalence obtained from hospital data, individuals with HAD will increase in number from 1314 men and 143 women in 2009 to 2204 men and 421 women in 2030. An estimated 22 men and 2 women with non-HIV dementia in 2009 will increase to 104 men and 12 women by 2030. The annual cost of care will increase from ~$29 million in 2009 to $53 million in 2030, mostly for full-time residential care. Conclusions: Neurocognitive disorders will place an increasing burden on resources, especially as those living with HIV age. Because it is unclear if HAD is an increased risk factor for non-HIV dementia, our calculations may be conservative.
Additional keywords: aging, cost of care, dementia.
References
[1] Access Economics, 2009. Keeping dementia front of mind: incidence and prevalence 2009–2050. Available online at: http://www.accesseconomics.com.au [accessed December 2010].[2] Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69 1789–99.
| Updated research nosology for HIV-associated neurocognitive disorders.Crossref | GoogleScholarGoogle Scholar |
[3] Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, et al Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63 822–7.
[4] Sacktor N, Skolasky RL, Cox C, Selnes O, Becker JT, Cohen B, et al Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatus. J Neurovirol 2010; 16 335–41.
| Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatus.Crossref | GoogleScholarGoogle Scholar |
[5] Scott JC, Woods SP, Carey CL, Weber E, Bondi MW, Grant I. Neurocognitive consequences of HIV infection in older adults: an evaluation of the “cortical” hypothesis. AIDS Behav 2010;
| Neurocognitive consequences of HIV infection in older adults: an evaluation of the “cortical” hypothesis.Crossref | GoogleScholarGoogle Scholar |
[6] Cysique LA, Maruff P, Bain MP, Wright E, Brew BJ. HIV and age do not substantially interact in HIV-associated neurocognitive impairment. J Neuropsychiatry Clin Neurosci 2011; 23 83–9.
| HIV and age do not substantially interact in HIV-associated neurocognitive impairment.Crossref | GoogleScholarGoogle Scholar |
[7] Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10 350–7.
| Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts.Crossref | GoogleScholarGoogle Scholar |
[8] Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21 1915–21.
| The prevalence and incidence of neurocognitive impairment in the HAART era.Crossref | GoogleScholarGoogle Scholar |
[9] Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75 2087–96.
| HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.Crossref | GoogleScholarGoogle Scholar |
[10] Murray JM, McDonald AM, Law MG. Rapidly ageing HIV epidemic among men who have sex with men in Australia. Sex Health 2009; 6 83–6.
| Rapidly ageing HIV epidemic among men who have sex with men in Australia.Crossref | GoogleScholarGoogle Scholar |
[11] Jain SK. Trends in mortality: by causes of death in Australia, the states and territories during 1971–92, and in statistical divisions and sub-divisions during 1991–92. Canberra: Australian Bureau of Statistics; 1994.
[12] Brew BJ. AIDS dementia complex. Handb Clin Neurol 2007; 85 79–91.
| AIDS dementia complex.Crossref | GoogleScholarGoogle Scholar |
[13] National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2010. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales; 2010.
[14] Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 2009; 4 163–74.
[15] Anthony I, Ramage S, Carnie F, Simmonds P, Bell J. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 2006; 111 529–38.
| Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy.Crossref | GoogleScholarGoogle Scholar |
[16] Australian Institute of Health and Welfare (AIHW) 2006. Dementia in Australia: national data analysis and development. Canberra: AIHW; 2007.
[17] Cysique L, Murray J, Dunbar M, Jeyakumar V, Brew B. A screening algorithm for HIV-associated neurocognitive disorders. HIV Med 2010; 11 642–9.
| A screening algorithm for HIV-associated neurocognitive disorders.Crossref | GoogleScholarGoogle Scholar |
[18] Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146 87–95.
